Trial reportInternational journal of clinical oncology2025
Concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with head and neck squamous cell carcinoma: survival analysis based on 2-year follow-up data.
Trial report in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs a follow-up study to our prospective phase II trial of concurrent chemoradiotherapy (CCRT) with weekly low-dose carboplatin for cisplatin-ineligible patients with head and neck squamous cell carcinoma (HNSCC), we assessed long-term survival (minimum follow-up of 2-year) and subgroup analysis by age and renal function.
methodsA prospective phase II study on CCRT with weekly low-dose carboplatin for cisplatin-ineligible HNSCC in 30 patients who were aged (≥ 75-year-old patients with 40 mL/min estimated glomerular filtration rate [eGFR] or better) or had renal dysfunction (< 75-year-old patients with 30-60 mL/min eGFR) was performed between July 2019 and January 2022 at three tertiary hospitals. Survival outcomes were investigated 2 years after this phase 2 trial were investigated. Furthermore, we compared the treatment outcome between ≥ 75 years group and < 75 years group.
resultsThe median follow-up time was 41.5 months. The 2-year recurrence-free survival (RFS) and 2-year overall survival (OS) rates of all patients were 70% and 86.7%, respectively. The 2-year RFS and OS of patients ≥ 75 years old was 92.3% and 100%, respectively, whereas those of patients < 75 years old was 52.9% (p = 0.175) and 76% (p = 0.157), respectively, showing no significant differences between the groups.
conclusionCCRT with weekly low-dose carboplatin in patients with cisplatin-ineligible HNSCC showed favorable survival outcomes irrespective of age and renal function. This study highlights a potentially promising treatment option for cisplatin-ineligible HNSCC patients.
trial registrationjRCTs031190028.
Indexed as
Identifiers
40323514What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.